Weekly Update

Hannah Deborah  Müller, Florian Posch, Christoph Suppan…Marija Balic


Citation: Müller, H.D., Posch, F., Suppan, C. et al. Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy. Ann Surg Oncol 26, 4274–4283 (2019). https://doi.org/10.1245/s10434-019-07741-w 

Synopsis: In a clinical, independent setting the value of the residual cancer burden (RCB) predictive performance was assessed. The authors confirm the RCB score as externally valid prognostic marker independent of molecular subtype for relapse-free survival and overall survival.

Hatem Soliman, Susanne Wagner, Darl D. Flake II…William Gradishar


Citation: Soliman, H., Wagner, S., Flake, D.D. et al. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Ann Surg Oncol 27, 765–771 (2020). https://doi.org/10.1245/s10434-019-08039-7 

Synopsis: Neo-adjuvant chemotherapy may facilitate complete surgical resection in breast cancer. Using microarray data, two commercial breast cancer prognostic scores (12-gene MS and 21-gene RS) were significant predictors of response to neo-adjuvant chemotherapy, though the 12-gene MS outperformed the 21-gene RS.

Listen to the ASO's new podcast, Speaking of SurgOnc®

Speaking of SurgOnc Speaking of SurgOnc® is a podcast brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology (SSO).

The series is hosted by ASO Deputy Editor Dr. Frederick L. (Rick) Greene, who will expand upon ideas from articles published in the Annals. Once a month, Dr. Greene will interview authors and leading experts in surgical oncology.

Listen to the podcast here.

ASO – The Leading Resource in Surgical Oncology

Annals of Surgical OncologyAnnals of Surgical Oncology (ASO) hails 2019 as a year of growth and influence with a 13% increase in editorials, the addition of a two new editorial sections and the introduction of “ASO Author Reflections.” ASO also had more than 1 million article downloads, a demonstration of the quality and relevance of the research published. Read more about ASO.

ASO is the journal of choice of surgical oncologists and cancer multidisciplinary teams worldwide regarding surgical oncology research and education, and benefits surgeons, oncologists, hematologists, radiologists, general practitioners, pathologists, researchers, academicians, and other clinical professionals interested in all aspects of the surgical treatment of cancer. ASO strives to improve the practice environment in which high-quality surgical oncology care is delivered, to enhance the quality of life and survival of the surgical patient with cancer.

Join the conversation! Follow the journal on Twitter and Facebook. Help to expand the reach of the journal to support the research and practice needs of surgical oncologists and their patients.

Scroll to Top